StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MESOBullishEarningsnews
High materiality8/10

Mesoblast reports FY2026 profitability; major Phase 3 readouts and expansions ahead

Aug 26, 2026, 8:35 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The results show improved profitability trajectory alongside strong RYONCIL adoption, expanding TAM via adult SR-aGvHD labeling and a pivotal CLBP readout, plus favorable financing. These catalysts can drive revaluation despite ongoing losses, especially given mid-2027 topline potential and a multi-billion TAM claim for rexlemestrocel-L.

AI summary

What happened, with direct paths to the underlying reporting

Mesoblast reports FY2026 gross profit of $103.6M on $120.3M revenue, with U.S. RYONCIL adoption boosting net revenue to $115.2M. The company plans label expansion to adults with SR-aGVHD and accelerates rexlemestrocel-L Phase 3 for chronic low back pain, with top-line readout due mid-CY2027, potentially unlocking a multi-billion-dollar market. Cash stands at $103M, plus a $125M five-year credit line.

  • FY2026 revenue $120.3M; gross profit $103.6M.
  • Ryoncil U.S. launch net revenue $115.2M; gross-to-net 13.4%.
  • Rexlemestrocel-L Phase 3 for CLBP: 350 patients treated; readout mid-CY2027.
  • Adults SR-aGvHD label expansion; Duchenne trial IND clearance.
  • Ending cash $103M; $125M five-year non-dilutive credit line.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event